Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ART 2713

Next Previous
Drug Profile

ART 2713

Alternative Names: ART-2713; ART27.13; AZD-1940; NEO-1940

Latest Information Update: 15 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca; NEOMED; Pfizer
  • Developer adMare BioInnovations; Artelo Biosciences; AstraZeneca
  • Class Analgesics; Antiemetics; Appetite stimulants; Benzimidazoles; Cyclohexanes; Fluorinated hydrocarbons; Small molecules; Sulfonamides
  • Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists; G protein-coupled receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Anorexia
  • Preclinical Cachexia
  • No development reported Cancer pain; Nausea and vomiting
  • Discontinued Neuropathic pain; Pain

Most Recent Events

  • 03 Sep 2025 Updated efficacy and adverse events data from a phase I/II trial in Anorexia released by Artelo Biosciences
  • 03 Sep 2025 Efficacy data from a phase I/II trial in Anorexia released by Artelo Biosciences
  • 03 Sep 2025 Artelo Biosciences plans a phase III registrational trial for Anorexia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top